Microscopic polyangiitis (MPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that affects small vessels especially renal glomeruli. We recently demonstrated that the abnormal formation and impaired degradation of neutrophil extracellular traps (NETs) could be crucially involved in the generation of myeloperoxidase (MPO)-ANCA and subsequent development of MPA. The aim of this study is to elucidate the enhanced formation and disordered regulation of NETs in patients with MPO-ANCA-associated MPA. Peripheral blood samples were obtained from 38 MPO-ANCA-associated MPA patients, 23 systemic lupus erythematosus (SLE) patients, and 8 healthy controls. First, IgG eluted from MPO-ANCA-associated MPA sera demonstrated high ability for NETs induction compared to healthy controls, and the ability correlated to the disease activity and was parallel to the ANCA affinity to MPO. Moreover, the NETs induction ability was absorbed by addition of recombinant human MPO in the IgG samples. These findings indicated the serum factor that induced NETs as MPO-ANCA. Next, low ability of MPO-ANCA-associated MPA serum for NETs degradation was determined. The ability was partially recovered by depletion of IgG from the sera; thus, the presence of serum factors that precluded NETs degradation besides IgG was suggested. Correspondingly, activity of DNase I, an important regulator of NETs, was generally low in MPO-ANCA-associated MPA similar to SLE. Furthermore, the presence of anti-NETs antibodies, which could interfere with the DNase I activity, was demonstrated in some MPO-ANCA-associated MPA sera. The collective evidence suggests that a vicious cycle through NETs and MPO-ANCA could be critically involved in the pathogenesis of MPO-ANCA-associated MPA.
Introduction
Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis that affects small vessels predominantly in the kidney. 1 Anti-myeloperoxidase (MPO) autoantibody, which is detected as peri-nuclear antineutrophil cytoplasmic antibody (ANCA) by immunofluorescent staining (IF), is frequently present in the serum. Although MPO is an intra-cytoplasmic granule mainly in neutrophils, it can be released through the plasma membrane when these cells are activated by pro-inflammatory cytokines, such as TNF-α. It is considered that pathogenic ANCA can bind to the cell surface MPO of the pro-inflammatory cytokine-primed neutrophils, which leads to excessive activation of neutrophils and subsequent destruction of small vasculature. 2 This concept called "ANCA-cytokine sequence theory" is commonly accepted as the critical part in the pathogenesis of MPO-ANCA-associated MPA. 3 However, it remains unrevealed why such pathogenic MPO-ANCA is produced.
Some patients under the antithyroid drug regimen, propylthiouracil (PTU), are known to develop MPA with production of MPO-ANCA. 4 Recently, we have demonstrated that the process of abnormal formation and impaired degradation of neutrophil extracellular traps (NETs) induced by PTU was critically involved in the generation of MPO-ANCA and subsequent development of MPA. [5] [6] [7] NETs represent the unique death of neutrophils, in which there is extracellular release of chromatin fibers and antibacterial cytoplasmic proteins, including MPO. 8 The process is an innate defense mechanism to trap and kill invading microbes. 9 Interestingly, NETs have been detected in glomerular crescents in patients diagnosed with MPA regardless of the absence of infectious agents. 10 Based on the collective evidence, we hypothesize that the persistent MPO in the PTU-induced protracted NETs could be recognized as an autoantigen by the immune system. 5 This hypothesis corresponds to the finding that NETs mediate the transfer of MPO to myeloid dendritic cells toward ANCA induction. 11 However, the majority of MPA patients develop the disease without administration of PTU or related drugs. Thus, we consider that there are mechanisms unrelated to PTU but with influence on the formation and regulation of NETs in MPA. 12 In this study, we first focused on the ability of serum IgG to induce NETs and then demonstrated the high ability of MPO-ANCA-associated MPA IgG for NETs induction. The ability for NETs induction was correlated to the disease activity and parallel to the ANCA affinity to MPO. Furthermore, the NETs induction ability was absorbed by addition of recombinant human MPO in the IgG samples. These findings 
Results

High ability of serum IgG from MPO-ANCA-associated MPA patients for NETs induction
First, we confirmed the high ability of MPO-ANCA-associated MPA IgG for NETs induction which was reported previously. 10 NETs induction was quantified by 2 independent methods, including IF for citrullinated histone 3 (Cit H3)-positive neutrophils (Figure 1 , A-G) and ELISA for MPO-DNA complexes in culture supernatants ( Figure 1H ). Since deimination of histones is an essential process for the generation of NETs, the detection of Cit H3-positive neutrophils is regarded as an accurate method to identify NETs. 13, 14 The MPO-DNA complexes in the serum and culture supernatants were shown to reflect the amounts of NETs in the tissue 10 and dish, 5 respectively. There was a significant correlation between the values of IF and ELISA (R 2 =0.2485, p<0.01); thus, the results indicated the reliability of these 2 methods (Supplemental Figure 1 ). In this experiment, neutrophils from healthy volunteers were pre-treated with TNF-α. When the TNF-α-primed neutrophils were incubated with serum IgG from MPO-ANCA-associated MPA patients, the rate of Cit H3-positive neutrophils was 16.6 ± 9.7 % ( Figure 1G ). This value was significantly higher than when the neutrophils were incubated with serum IgG from healthy controls (3. 
MPO-ANCA as NETs induction factor in MPO-ANCA-associated MPA serum
In order to determine that the NETs induction ability of MPO-ANCA-associated MPA IgG could be caused by MPO-ANCA, recombinant human MPO was added to the IgG samples. When neutrophils were incubated with the anti-human MPO monoclonal antibody, NETs were induced (Figure 2A ). On the other hand, the NETs induction was inhibited by addition of recombinant MPO dose-dependently ( Figure 2 , B and C).
Similarly, the NETs induction ability of MPO-ANCA-associated MPA IgG was absorbed by the addition of MPO (Figure 2 , D-G). These findings indicated that the NETs induction factor in MPO-ANCA-associated MPA serum was MPO-ANCA.
Association of NETs induction ability with vasculitis activity and MPO-ANCA affinity
Next, we determined that the NETs induction ability of MPO-ANCA-associated MPA IgG was correlated to the disease activity as represented by the Birmingham Vasculitis Activity Scores (BVAS) ( Figure 3A ). The result was in contrast to the finding in SLE patients that the NETs induction ability did not show a significant correlation to the disease activity as represented by the SLE disease activity index (SLEDAI) (Supplemental Figure 2 ). Although MPO-ANCA is a useful diagnostic marker of MPA, it is known that the disease activity sometimes dissociates from the ANCA titer. 15 Correspondingly, the NETs induction ability of MPO-ANCA-associated MPA IgG did not show a significant correlation to the MPO-ANCA titer in our patients ( Figure 3B ).
On the other hand, good association between MPO-ANCA affinity and disease activity was reported with clinical evidence. 16 According to this finding, we determined if the NETs induction ability of MPO-ANCA-associated MPA IgG would be correlated to the MPO-ANCA affinity, which was measured by the competitive inhibitory ELISA as previously described. 16 Among 9 patients with MPO-ANCA-associated MPA included in this study, 4 patients had high affinity ANCA; whereas, 5 patients had low affinity ANCA (Supplemental Figure 3A ). In consistence with the earlier report, 16 BVAS were significantly higher in patients with high affinity MPO-ANCA than with low affinity MPO-ANCA (Supplemental Figure 3B ). As expected, NETs induction ability of serum IgG from patients with high affinity MPO-ANCA was significantly higher than that from patients with low affinity MPO-ANCA ( Figure 3C ).
Low ability of MPO-ANCA-associated MPA serum for NETs degradation
It was reported that sera from healthy individuals could digest NETs effectively, but the sera from SLE patients had low ability for NETs degradation. 17 We determined if the sera from MPO-ANCA-associated MPA patients would be impotent to digest NETs similar to SLE. For this purpose, 10 % serum was added to NETs, which were induced on healthy donor neutrophils by phorbol myristate acetate (PMA) (Supplemental Figure   4 ). Sera from healthy controls could digest the PMA-induced NETs almost completely (NETs degradation rates more than 80 %). In contrast, most MPO-ANCA-associated MPA and SLE sera examined in this study showed impaired degradation of the PMA-induced NETs (NETs degradation rates less than 80 %) ( Figure 4, A and B) . The NETs degradation rates of MPO-ANCA-associated MPA and SLE sera were 47.4 ± 24.2 % and 48.8 ± 21.7 %, respectively. Both rates were significantly lower than that of healthy controls (91.5 ± 5.1 %) ( Figure 4B ).
Low DNase I activity in MPO-ANCA-associated MPA serum
In order to eliminate the NETs induction effects by MPO-ANCA-associated MPA IgG on NETs digestion, NETs degradation ability of IgG-depleted serum was examined.
Results indicated that the NETs degradation ability was recovered in some samples by
IgG-depletion (6 out of 15 samples) ( Figure 5A , Group 1). At this time, although the mean value of NETs degradation ability tended to increase by IgG-depletion, there was no significant difference between the sera with and without IgG-depletion ( Figure 5B ).
These findings suggested the presence of other serum factors that precluded NETs degradation in MPO-ANCA-associated MPA besides IgG. In particular, NETs are known to be digested by serum DNase I physiologically. It has been reported that DNase I activity in the serum was generally low in SLE, 18 Figure 5B ).
Presence of anti-NETs antibodies in MPO-ANCA-associated MPA
The NETs degradation ability in sera was increased by depletion of IgG in some MPO-ANCA-associated MPA patients ( Figure 5A Figure 7A ). The amount of anti-NETs antibodies was not correlated to the titer of MPO-ANCA in the serum ( Figure 7B ). In addition, the intervention of anti-MPO antibody did not inhibit the NETs degradation by DNase I (Figure 7C ).
Discussion
Although NETosis is an essential defense mechanism, its disorder could be related to autoimmune diseases, including SLE 20,21 and rheumatoid arthritis. 22 In the present study, we demonstrated 3 diverse disorders in MPO-ANCA-associated MPA serum, which were related to the formation or regulation of NETs. Secondly, as reported in SLE, 17 NETs degradation ability in the serum was significantly lower in MPO-ANCA-associated MPA patients than healthy controls. The serum DNase I activity is generally low in SLE, 18 and the low levels of DNase I activity in the serum could cause the disordered elimination of apoptotic cells in SLE. 19 Further investigation is needed to clarify if the disorder of scavenger system for apoptotic cells is involved in the pathogenesis of MPO-ANCA-associated MPA, as well as in SLE.
Although we should take into account the possibility that the low level of DNase I activity in the sera of these patients could be caused by the consumption of DNase I in order to eliminate NETs, it seems unlikely relevant because the serum DNase I activity in these patients is not correlated to the disease activity. It is rather considered that the low level DNase I activity in the serum, which may be defined genetically, is a common feature between MPO-ANCA-associated MPA and SLE. In addition, the low levels of pathogenesis of MPO-ANCA-associated MPA, novel therapies can be considered. It is known that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 23 and peptidylarginine deiminase 4 (PAD4) 13 are essential for the generation of NETs.
Blockades for NETs generation, such as NADPH oxidase inhibitors 24 and PAD4
inhibitors, 25 could be candidates to cause interference in the "NETs-ANCA vicious cycle" in the pathogenesis of MPA. Although further examinations using animal models and prospective clinical trials are needed to establish novel therapeutic strategies for the treatment of MPO-ANCA-associated MPA, we have a foresight for future studies. 
